Skip to main content
    N

    Nuvectis Pharma Inc (NVCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.11
    -1.13 (-5.58%)

    Market Cap: $696.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Nuvectis Pharma Inc (NVCT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nuvectis Pharma (NVCT) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Nuvectis Pharma reported EPS of -$1.02, below the -$0.22 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(6/20)
    Avg Surprise
    -30.93%

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.38
    Range-$0.79 - -$0.21
    8 analysts
    Revenue Consensus
    N/A
    RangeN/A
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.28
    Range-$0.34 - -$0.22
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago-$0.33+13.8%
    30d ago-$0.33+13.8%
    7d ago-$0.33+13.8%
    Current-$0.28
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    NVCT has an expected report date of Feb 9, 2027.

    NVCT Earnings Call

    The latest NVCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 20 quarters below that had an estimate, NVCT beat 6, missed 13 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 363.64% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.02-$0.22-$0.28 - -$0.21-363.64%MissN/A63 up, 0 downNov 4, 2026
    Jun 30, 2026-$0.30-$0.25-$0.29 - -$0.24-20.00%MissN/A52 up, 0 downAug 4, 2026
    Mar 31, 2026-$0.26-$0.31-$0.33 - -$0.29+16.13%BeatN/A50 up, 0 downMay 5, 2026
    Dec 31, 2025-$0.31-$0.31-$0.35 - -$0.200.00%In lineN/A50 up, 1 downFeb 11, 2026
    Sep 30, 2025-$0.44-$0.25-$0.28 - -$0.21-76.00%MissN/A62 up, 3 downNov 4, 2025
    Jun 30, 2025-$0.30-$0.25N/A-20.00%MissN/AN/A0 up, 0 downAug 5, 2025
    Mar 31, 2025-$0.27-$0.25N/A-8.00%MissN/AN/A0 up, 0 downMay 6, 2025
    Dec 31, 2024-$0.35-$0.26N/A-36.35%MissN/AN/A0 up, 0 downFeb 25, 2025
    Sep 30, 2024-$0.24-$0.25-$0.26 - -$0.25+4.00%BeatN/A30 up, 0 downNov 5, 2024
    Jun 30, 2024-$0.26-$0.31N/A+16.13%BeatN/A20 up, 0 downAug 6, 2024
    Mar 31, 2024-$0.25-$0.39-$0.40 - -$0.39+35.90%BeatN/A30 up, 0 downMay 7, 2024
    Dec 31, 2023-$0.41-$0.36-$0.37 - -$0.36-13.89%MissN/A20 up, 0 downMar 5, 2024
    Sep 30, 2023-$0.37-$0.34-$0.40 - -$0.27-8.82%MissN/A30 up, 0 downNov 8, 2023
    Jun 30, 2023-$0.38-$0.21-$0.41 - -$0.20-80.95%MissN/A30 up, 0 downAug 9, 2023
    Mar 31, 2023-$0.27-$0.45-$0.46 - -$0.41+40.00%BeatN/A30 up, 0 downMay 10, 2023
    Dec 31, 2022-$0.49-$0.38N/A-28.95%MissN/AN/A0 up, 0 downMar 7, 2023
    Sep 30, 2022-$0.42-$0.27-$0.28 - -$0.26-55.56%MissN/A30 up, 0 downNov 8, 2022
    Jun 30, 2022-$0.28-$0.24-$0.27 - -$0.20-16.67%MissN/A31 up, 0 downAug 5, 2022
    Mar 31, 2022-$0.32-$0.22-$0.24 - -$0.22-45.45%MissN/A20 up, 0 downMay 10, 2022
    Dec 31, 2021-$0.48-$0.85-$0.85 - -$0.85+43.53%BeatN/A10 up, 0 downJan 14, 2022
    Sep 30, 2021-$24.43N/AN/AN/AN/AN/AN/AN/AOct 21, 2021
    Last 21 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.32, after -$1.10 the year before. It was -$24.91 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.32N/A
    Dec 31, 2024-$1.10N/A
    Dec 31, 2023-$1.43N/A
    Dec 31, 2022-$1.51N/A
    Dec 31, 2021-$24.91N/A

    Earnings Calls

    The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,7706

    2026Q3 Earnings Call

    Opening remarks

    Ron Bentsur Chairman and CEO Thank you, and good morning, everyone. Before we begin, I would like to remind everyone that statements made during this call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2000. These statements are based on management's current expectations and our interpretation of information available to date, and they are subject to substantial risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the section titled “Risk Factors” in our quarterly report on Form 10-Q for the quarter ended September 30, 2026, and our other filings with the SEC. These risks are not exhaustive, and new risks emerge from time to time. Any forward-looking statements made on this call speak only as of today, Wednesday, November 4, 2026. Nuvectis undertakes no obligation to update or revise them except as required by law. Okay. Now let's get to the interesting part of this call. Today is the first time we are hosting a call alongside the release of our quarterly results, and the reason is simple: the third quarter was transformational for Nuvectis. We have a great deal to share with you. We have transformed Nuvectis into a late-stage development company with the addition of two exciting drug candidates with best-in-class potential through our licensing agreement for ex-China rights with our new partner, Haisco. These additions have fundamentally changed the opportunity ahead of us. Our lead drug candidate, ciprocfeltin, which we also interchangeably refer to as NXP-100, is an oral complement factor B inhibitor for once-daily oral administration that is approved in China for the treatment of newly diagnosed paroxysmal nocturnal hemoglobinuria, or PNH, in short, and is in development for the treatment of other complement-mediated diseases, including an ongoing Phase 3 study in IgA nephropathy and a Phase 2 study in lupus nephritis, both being conducted in China by our partner, Haisco. The second drug, NXP-200, is an oral, brain-penetrant paradox-breaker BRAF inhibitor for the treatment of BRAF-mutated solid tumors, and I will expand on these two products and on our legacy compound, NXP-900, during the call. We closed the licensing deal with Haisco in late June, after which we completed a follow-on offering of $150 million in gross proceeds that was anchored by leading healthcare-dedicated institutional investors. Also in the third quarter, we placed approximately $37 million with a single healthcare-dedicated fund through our ATM facility. We ended the quarter with approximately $140 million in cash, which we expect will fund our operations into the second half of 2029 and, importantly, beyond multiple value inflection points.

    Frequently Asked Questions About NVCT

    When is Nuvectis Pharma's next earnings date?

    Nuvectis Pharma's next earnings report is expected for Feb 9, 2027.

    Did NVCT beat earnings estimates last quarter?

    No. Nuvectis Pharma reported EPS of -$1.02 for the quarter ended Sep 30, 2026, below the -$0.22 estimate by 363.64%.

    What EPS do analysts expect from NVCT next quarter?

    The consensus EPS estimate for Nuvectis Pharma for the quarter ending Dec 31, 2026 is -$0.38 from 8 analysts, with estimates from -$0.79 to -$0.21.

    How often does NVCT beat earnings estimates?

    Nuvectis Pharma beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -63.48%.